City Therapeutics, a clinical-stage biotechnology company developing RNA interference therapies, has filed with the SEC to raise up to $100 million in an initial public offering. The Cambridge, Massachusetts-based company is advancing RNAi-based treatments for diseases including thromboembolic conditions, Stargardt disease type 1 and anemia of chronic disease, with its lead candidate already in a Phase 1 clinical trial.

Company Background

Founded in 2023, City Therapeutics develops RNA interference therapeutics designed to silence the expression of disease-relevant proteins. The company says its pipeline focuses on indications with significant unmet medical need where disease biology may support RNAi-mediated knockdown as a differentiated therapeutic approach.

Its lead program, CITY-FXI, is a City-engineered GalNAc-conjugated small interfering RNA therapeutic candidate targeting Factor XI, or FXI. City Therapeutics initiated a Phase 1 clinical trial for CITY-FXI in 2026.

The company booked $14 million in revenue for the 12 months ended June 30, 2026. It has generated revenue through its development-stage operations, although the filing details provided do not specify the source of that revenue.

IPO Details

City Therapeutics plans to list on the Nasdaq under the ticker CTY. The company is seeking to raise up to $100 million, although no pricing range, share count or valuation terms have been disclosed.

The company filed its IPO confidentially on July 15, 2026. Goldman Sachs, Jefferies, Stifel and Oppenheimer & Co. are serving as joint bookrunners.

The proposed offering would give public-market investors exposure to a clinical-stage biotechnology company focused on RNA interference therapeutics.

Clinical Development & Market Opportunities

CITY-FXI is currently being evaluated in a Phase 1 study. According to City Therapeutics, initial data from the first three cohorts of the single-ascending-dose portion of the trial in healthy volunteers showed that the candidate was generally well tolerated.

The company reported more than 60% FXI knockdown following a single 15 mg subcutaneous dose, close to 80% knockdown after a single 50 mg dose, and 85% knockdown three weeks after a single 150 mg dose.

City Therapeutics expects to report additional data from the single-ascending-dose portion of the Phase 1 study in late 2026. Beyond CITY-FXI, the company is developing programs addressing Stargardt disease type 1 and anemia of chronic disease.

Risks & Challenges

As a clinical-stage biotech, City Therapeutics remains dependent on the continued development of its pipeline and the outcome of clinical trials. CITY-FXI is still in Phase 1, meaning its reported results are based on an early-stage clinical study and additional testing will be required to establish the candidate’s safety and potential efficacy.

The company also faces the broader risks associated with biotechnology development, including clinical, regulatory and commercialization uncertainties. No pricing terms have yet been disclosed for the proposed IPO, leaving the eventual valuation and capital structure of the offering undetermined.

Closing Paragraph

City Therapeutics is entering the IPO market with a developing RNA interference platform and a lead candidate that has already generated early Phase 1 data. With up to $100 million targeted and additional CITY-FXI data expected later in 2026, the proposed Nasdaq listing would provide the company with a potential source of public-market capital as it advances its clinical pipeline.